SOURCE: Barrier Therapeutics, Inc.

September 13, 2005 16:01 ET

Barrier Therapeutics Hosts Analyst and Investor Day

Presentation to Be Webcast Live

PRINCETON, NJ -- (MARKET WIRE) -- September 13, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that the Company will host its First Analyst and Investor Day on Tuesday, September 20, 2005. The event, including the presentation slides, will be webcast live via the Internet beginning at approximately 12:00 pm EDT.

Barrier Therapeutics' management will review key updates on areas encompassing the Company's commercial activities, marketed products and product pipeline. In addition, Jonathan S. Weiss, M.D., a practicing dermatologist and clinical investigator affiliated with Emory University, will join management as part of the presentation program.

To access the live audio and presentation slides, please visit the Investor Relations section of the Company's website at http://www.barriertherapeutics.com. An archived version of the presentation will be available at the same location for 30 days.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and recently obtained the Canadian distribution rights for Vaniqa® (eflornithine hydrochloride) Cream 13.9% for slowing the growth of unwanted facial hair in women. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include one for the treatment of diaper dermatitis complicated by candidiasis, which is under FDA review, and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, onychomycosis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada.

Web site: http://www.barriertherapeutics.com.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    609-945-1202

    Noonan Russo
    Emily Poe
    212-845-4266